Publication:
2-(fluorine-18)-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography after breast conserving surgery: Correlation with molecular markers of breast cancer

Simple item page
dc.contributor.authorTUROĞLU, HALİL TURGUT
dc.contributor.authorsOzguven, Salih; Inanir, Sabahat; Turoglu, Halil Turgut; Erdil, Tanju Yusuf; Ugurlu, Mustafa Umit; Gulluoglu, Bahadir
dc.date.accessioned2022-03-14T08:13:40Z
dc.date.available2022-03-14T08:13:40Z
dc.date.issued2016
dc.description.abstractAim: To investigate the role of 2-(fluorine-18)-fluoro-2-deoxy-D-glucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT) early after breast-conserving surgery (BCS) in patients with breast cancer (BC) and whether we can determine which molecular biomarkers of breast carcinoma put the patients at risk. Materials and Methods: This retrospective study involved 88 patients with histologically proven T1 or T2 BC, who were treated with BCS and underwent F-18-FDG PET/CT study. The correlation between biological markers (estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 [HER2], and Ki-67) of the primary tumor and F-18-FDG PET/CT findings was analyzed. Results: F-18-FDG PET/CT demonstrated the presence of BC disease (locoregional disease [LRD], distant metastases, or contralateral BC) in 26 of 88 patients (29.5%). Regarding immunohistochemical profiles, BC expressing high levels of Ki-67 were associated with an increased percentage of LRD, which was the major recurrence pattern on F-18-FDG PET/CT. Although the BC disease was observed more commonly in patients with HER2 positivity compared to those of HER2 negative, the difference did not reach statistical significance. The patients with T2 tumor or a higher histopathological grade had a higher percentage of BC disease. Conclusions: This study demonstrated that patients with early stage BC treated with BCS have a remarkable risk of the presence of BC even early after surgery, and there was a clinically important relationship between F-18-FDG PET/CT findings and biological markers of BC. These findings suggest that high-risk molecular biomarkers (Ki-67, HER2) can be taken into account in the decision-making the process for both preoperative imaging and planning of the surgical approach.
dc.identifier.doi10.4103/0972-3919.181848
dc.identifier.eissn0974-0244
dc.identifier.issn0972-3919
dc.identifier.pubmed27385883
dc.identifier.urihttps://hdl.handle.net/11424/241121
dc.identifier.wosWOS:000379319300002
dc.language.isoeng
dc.publisherMEDKNOW PUBLICATIONS & MEDIA PVT LTD
dc.relation.ispartofINDIAN JOURNAL OF NUCLEAR MEDICINE
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBreast neoplasms
dc.subjectfluorodeoxyglucose F18
dc.subjecthuman epidermal growth factor receptor 2
dc.subjectKi-67 antigen
dc.subjectmastectomy
dc.subjectpositron emission tomography
dc.subjectsegmental
dc.subjectF-18-FDG PET/CT
dc.subjectSUBTYPES
dc.subjectTHERAPY
dc.subjectFDG
dc.subjectMASTECTOMY
dc.subjectRECEPTOR
dc.subjectIMPACT
dc.title2-(fluorine-18)-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography after breast conserving surgery: Correlation with molecular markers of breast cancer
dc.typearticle
dspace.entity.typePublication
local.avesis.idc7eaa1e0-8f4e-48f5-80f6-6265bfd68b3b
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages6
oaire.citation.endPage171
oaire.citation.issue3
oaire.citation.startPage166
oaire.citation.titleINDIAN JOURNAL OF NUCLEAR MEDICINE
oaire.citation.volume31
relation.isAuthorOfPublicationa3244974-56b7-4008-a95e-e2516a154baa
relation.isAuthorOfPublication.latestForDiscoverya3244974-56b7-4008-a95e-e2516a154baa

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Ozguven et al. - 2016 - 2-(fluorine-18)-fluoro-2-deoxy-D-glucose positron .pdf
Size:
687.66 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs